Imipenem–cilastatin versus piperacillin–tazobactam as monotherapy in febrile neutropenia
Authors:
- 25 March 2010
- journal article
- research article
- Published by Wiley in Pediatrics International
- Vol. 52 (2) , 262-267
Abstract
In view of the recent trend toward monotherapy in the treatment of febrile neutropenia, we evaluated the clinical efficacy and safety of imipenem-cilastatin versus piperacillin-tazobactam as an empiric therapy for febrile neutropenia in children with malignant diseases. Febrile neutropenic patients received either imipenem-cilastatin or piperacillin-tazobactam randomly. Improvement without any changes in the initial antibiotic treatment was defined as "success" and improvement with modification of the initial treatment and death was defined as "failure". Over 12 months, 99 febrile neutropenic episodes were treated with monotherapy in 63 patients with a median age of 5 years. At admission, median absolute neutrophil count was 50/mm(3) and in 67% of episodes, neutrophil count was under 100/mm(3). Median duration of neutropenia was 5 days. In 22% of episodes, neutropenia persisted for more than 10 days. Piperacillin-tazobactam was used in 52 episodes and imipenem-cilastatin was used in 47 episodes. There was no difference between groups in terms of age, sex, primary diseases, neutrophil count or duration of neutropenia. In the whole group, the success rate was 67% and the failure rate was 33%, whereas in the piperacillin-tazobactam group, the rates were 71% and 29%; and in the imipenem-cilastatin group they were 62% and 38%, respectively (P > 0.05). There were no deaths. No major adverse effects were seen in either group. Although failure was slightly higher in the imipenem-cilastatin group, this was statistically insignificant. Both of these antibiotics can be used safely for initial empirical monotherapy of febrile neutropenia.Keywords
This publication has 34 references indexed in Scilit:
- The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropeniaEuropean Journal of Cancer, 2009
- A prospective, randomized study comparing cefozopran with piperacillin–tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disordersPediatric Blood & Cancer, 2008
- Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter surveyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East EnglandPediatric Blood & Cancer, 2006
- Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patientsClinical Microbiology and Infection, 2006
- MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized ComparisonPediatric Hematology and Oncology, 2006
- An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patientsClinical Microbiology and Infection, 2005
- Use of imipenem as empirical treatment of febrile neutropeniaInternational Journal of Antimicrobial Agents, 2003
- Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemiaSupportive Care in Cancer, 2002
- Initial empirical antibiotic therapy for neutropenic fever: Analysis of the causes of deathSupportive Care in Cancer, 1996